Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors.
Biomarkers
Circular RNAs (circRNAs)
Liquid biopsy
Neuroendocrine tumors (NETs)
Tumor-educated platelets (TEPs)
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
16 08 2023
16 08 2023
Historique:
received:
29
05
2023
accepted:
04
08
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment. We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18-80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group. Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results. Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs.
Sections du résumé
BACKGROUND
Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment.
METHODS
We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18-80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group.
RESULTS
Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results.
CONCLUSIONS
Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs.
Identifiants
pubmed: 37587471
doi: 10.1186/s12967-023-04417-8
pii: 10.1186/s12967-023-04417-8
pmc: PMC10428534
doi:
Substances chimiques
RNA, Circular
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
548Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.
pubmed: 35294740
Basuroy R, Bouvier C, Ramage JK, Sissons M, Kent A, Srirajaskanthan R. Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2018;107(1):42–9.
pubmed: 29550809
Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023;21(1):118.
pubmed: 36774504
pmcid: 9922467
Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–77.
pubmed: 22525418
Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016;5(5):174–87.
pubmed: 27582247
pmcid: 5045519
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.
pubmed: 23446348
Tatomer DC, Wilusz JE. An unchartered journey for ribosomes: circumnavigating circular RNAs to produce proteins. Mol Cell. 2017;66(1):1–2.
pubmed: 28388436
Maass PG, Glazar P, Memczak S, Dittmar G, Hollfinger I, Schreyer L, et al. A map of human circular RNAs in clinically relevant tissues. J Mol Med. 2017;95(11):1179–89.
pubmed: 28842720
Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–90.
pubmed: 32366901
Zhao X, Zhong Y, Wang X, Shen J, An W. Advances in circular RNA and its applications. Int J Med Sci. 2022;19(6):975–85.
pubmed: 35813288
pmcid: 9254372
Xia S, Feng J, Chen K, Ma Y, Gong J, Cai F, et al. CSCD: a database for cancer-specific circular RNAs. Nucleic Acids Res. 2018;46(D1):D925–9.
pubmed: 29036403
Alhasan AA, Izuogu OG, Al-Balool HH, Steyn JS, Evans A, Colzani M, et al. Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood. 2016;127(9):e1–11.
pubmed: 26660425
pmcid: 4797142
Feng J, Chen W, Dong X, Wang J, Mei X, Deng J, et al. CSCD2: an integrated interactional database of cancer-specific circular RNAs. Nucleic Acids Res. 2022;50(D1):D1179–83.
pubmed: 34551437
Joosse SA, Pantel K. Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell. 2015;28(5):552–4.
pubmed: 26555171
Roweth HG, Battinelli EM. Lessons to learn from tumor-educated platelets. Blood. 2021;137(23):3174–80.
pubmed: 33940594
pmcid: 8351883
Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–76.
pubmed: 26525104
pmcid: 4644263
Wang Y, Zhang H, Li H, Xiong J, Wang J, Huang Y. Application of tumor-educated platelets as new fluid biopsy markers in various tumors. Clin Transl Oncol. 2023;25(1):114–25.
pubmed: 36284061
Poulet G, Massias J, Taly V. Liquid biopsy: general concepts. Acta Cytol. 2019;63(6):449–55.
pubmed: 31091522
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.
pubmed: 26742109
Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135–56.
pubmed: 22262080
Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
pubmed: 32272208
Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20(11):1666–70.
pubmed: 25234927
pmcid: 4201819
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.
pubmed: 19910308
Puliani G, Di Vito V, Feola T, Sesti F, Centello R, Pandozzi C, et al. NETest: a systematic review focusing on the prognostic and predictive role. Neuroendocrinology. 2022;112(6):523–36.
pubmed: 34515175
Kuznetsov HS, Marsh T, Markens BA, Castano Z, Greene-Colozzi A, Hay SA, et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2012;2(12):1150–65.
pubmed: 22896036
pmcid: 3517696
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.
pubmed: 31395983
D’Ambrosi S, Visser A, Antunes-Ferreira M, Poutsma A, Giannoukakos S, Sol N, et al. The analysis of platelet-derived circRNA repertoire as potential diagnostic biomarker for non-small cell lung cancer. Cancers. 2021;13(18):4644.
pubmed: 34572871
pmcid: 8468408
Xu L, Li X, Li X, Wang X, Ma Q, She D, et al. RNA profiling of blood platelets noninvasively differentiates colorectal cancer from healthy donors and noncancerous intestinal diseases: a retrospective cohort study. Genome Med. 2022;14(1):26.
pubmed: 35236405
pmcid: 8889759
Xiao R, Liu C, Zhang B, Ma L. Tumor-educated platelets as a promising biomarker for blood-based detection of renal cell carcinoma. Front Oncol. 2022;12:844520.
pubmed: 35321426
pmcid: 8936192
Heinhuis KM, In’t Veld S, Dwarshuis G, van den Broek D, Sol N, Best MG, et al. RNA-sequencing of tumor-educated platelets, a novel biomarker for blood-based sarcoma diagnostics. Cancers. 2020;12(6):1372.
pubmed: 32471035
pmcid: 7352477
Tjon-Kon-Fat LA, Lundholm M, Schroder M, Wurdinger T, Thellenberg-Karlsson C, Widmark A, et al. Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. Prostate. 2018;78(1):48–53.
pubmed: 29094381
Waqar W, Asghar S, Manzoor S. Platelets’ RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules. PLoS ONE. 2021;16(9):e0256739.
pubmed: 34469466
pmcid: 8409664
Gerard L, Garcia J, Gauthier A, Lopez J, Durand A, Hervieu V, et al. ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN-NEC pilot study. Neuroendocrinology. 2021;111(10):951–64.
pubmed: 33099543
Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto K, et al. Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. Biochem Biophys Res Commun. 2021;552:120–7.
pubmed: 33744759
Dou N, Hu Q, Li L, Wu Q, Li Y, Gao Y. USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2. Int J Biol Sci. 2020;16(9):1648–57.
pubmed: 32226309
pmcid: 7097920
Chen S, Chen X, Li Z, Mao J, Jiang W, Zhu Z, et al. Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms. Sci Rep. 2022;12(1):6445.
pubmed: 35440702
pmcid: 9018837
Liu C, Chen Z, Fang M, Qiao Y. MicroRNA let-7a inhibits proliferation of breast cancer cell by downregulating USP32 expression. Transl Cancer Res. 2019;8(5):1763–71.
pubmed: 35116927
pmcid: 8799222
Hu W, Wei H, Li K, Li P, Lin J, Feng R. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif. 2017;50(4):e12343.
pubmed: 28597490
pmcid: 6529138
Wang Y, Zhou D, Kong Y, Yang Q, Ding Y, Wang W. USPs in pancreatic ductal adenocarcinoma: a comprehensive bioinformatic analysis of expression, prognostic significance, and immune infiltration. Biomed Res Int. 2022;2022:6109052.
pubmed: 36582601
pmcid: 9794441
Lobo GP, Fulmer D, Guo L, Zuo X, Dang Y, Kim SH, et al. The exocyst is required for photoreceptor ciliogenesis and retinal development. J Biol Chem. 2017;292(36):14814–26.
pubmed: 28729419
pmcid: 5592663
Gao P, Wu B, Ding Y, Yin B, Gu H. circEXOC5 promotes acute lung injury through the PTBP1/Skp2/Runx2 axis to activate autophagy. Life Sci Alliance. 2023;6(1):e202201468.
pubmed: 36302650
White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett. 2009;583(12):1817–24.
pubmed: 19433088
pmcid: 2743239
Jin SH, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, Yuasa Y. IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer. 2008;122(5):1040–6.
pubmed: 17957782
Xie Y, Yan J, Cutz JC, Rybak AP, He L, Wei F, et al. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta. 2012;1822(6):875–84.
pubmed: 22406297
White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB, et al. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol. 2010;10:125.
pubmed: 20977743
pmcid: 2988069
Deng Z, Wang L, Hou H, Zhou J, Li X. Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/beta-catenin signaling. Int J Oncol. 2016;48(1):153–60.
pubmed: 26549344
Aspenstrom P, Richnau N, Johansson AS. The diaphanous-related formin DAAM1 collaborates with the Rho GTPases RhoA and Cdc42, CIP4 and Src in regulating cell morphogenesis and actin dynamics. Exp Cell Res. 2006;312(12):2180–94.
pubmed: 16630611
Mei J, Xu B, Hao L, Xiao Z, Liu Y, Yan T, et al. Overexpressed DAAM1 correlates with metastasis and predicts poor prognosis in breast cancer. Pathol Res Pract. 2020;216(3):152736.
pubmed: 31757662
Liu G, Yan T, Li X, Sun J, Zhang B, Wang H, et al. Daam1 activates RhoA to regulate Wnt5a-induced glioblastoma cell invasion. Oncol Rep. 2018;39(2):465–72.
pubmed: 29207169
Mei J, Huang Y, Hao L, Liu Y, Yan T, Qiu T, et al. DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p. Pathol Res Pract. 2019;215(7):152452.
pubmed: 31104928
Hu X, Zhu H, Feng S, Wang C, Ye Y, Xiong X. Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. Front Genet. 2022;13:1006357.
pubmed: 36246598
pmcid: 9556949
Dai T, Ye L, Deng M, Lin G, Liu R, Yu H, et al. Upregulation of TMCO3 promoting tumor progression and contributing to the poor prognosis of hepatocellular carcinoma. J Clin Transl Hepatol. 2022;10(5):913–24.
pubmed: 36304514
pmcid: 9547258
Duan C, Wang H, Chen Y, Chu P, Xing T, Gao C, et al. Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy. Cancer Cell Int. 2018;18:21.
pubmed: 29467591
pmcid: 5816515
Shi Y, Qian ZR, Zhang S, Li W, Masugi Y, Li T, et al. Cell cycle protein expression in neuroendocrine tumors: association of CDK4/CDK6, CCND1, and phosphorylated retinoblastoma protein with proliferative index. Pancreas. 2017;46(10):1347–53.
pubmed: 28991877
pmcid: 5645256
Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res. 2012;18(17):4612–20.
pubmed: 22761470